OTCMKTS:ABLYF

Ablynx Stock Forecast, Price & News

$50.63
0.00 (0.00 %)
(As of 04/30/2019)
Add
Compare
Today's Range
$50.63
$50.63
50-Day Range
$50.63
$50.63
52-Week Range
$12.50
$55.04
VolumeN/A
Average Volume5,063 shs
Market Capitalization$3.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.99
30 days | 90 days | 365 days | Advanced Chart
Receive ABLYF News and Ratings via Email

Sign-up to receive the latest news and ratings for Ablynx and its competitors with MarketBeat's FREE daily newsletter.


Ablynx logo

About Ablynx

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.44 out of 5 stars

Medical Sector

1752nd out of 2,099 stocks

Biological Products, Except Diagnostic Industry

187th out of 198 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ablynx (OTCMKTS:ABLYF) Frequently Asked Questions

What stocks does MarketBeat like better than Ablynx?

Wall Street analysts have given Ablynx a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ablynx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Ablynx's stock price been impacted by Coronavirus?

Ablynx's stock was trading at $50.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABLYF shares have increased by 0.0% and is now trading at $50.63.
View which stocks have been most impacted by COVID-19
.

Who are Ablynx's key executives?

Ablynx's management team includes the following people:
  • Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)
  • Mr. Wim Ottevaere, Chief Financial Officer (Age 62)
  • Mr. Piet Houwen, Chief Operations Officer
  • Dr. Robert Friesen Ph.D., Chief Scientific Officer
  • Lies Vanneste, Director of Investor Relations

Who are some of Ablynx's key competitors?

What is Ablynx's stock symbol?

Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF."

How do I buy shares of Ablynx?

Shares of ABLYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ablynx's stock price today?

One share of ABLYF stock can currently be purchased for approximately $50.63.

How much money does Ablynx make?

Ablynx has a market capitalization of $3.81 billion and generates $62.73 million in revenue each year.

What is Ablynx's official website?

The official website for Ablynx is www.ablynx.com.

Where are Ablynx's headquarters?

Ablynx is headquartered at TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052.

How can I contact Ablynx?

Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The company can be reached via phone at 329-262-0000.


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.